![](/img/cover-not-exists.png)
Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI® and BRAMITOB® (Tobramycin inhalation solutions)
John E. Moore, Yasunori Maeda, Colin E. Goldsmith, Jacqueline C. Rendall, J. Stuart ElbornVolume:
9
Year:
2010
Language:
english
DOI:
10.1016/j.jcf.2010.03.005
File:
PDF, 112 KB
english, 2010